Skip to content

KLRS KLRS Change In Fair Value Of Derivative Liability

Change In Fair Value Of Derivative Liability at other companies

SANUWAVE Health, Inc. logo
SANUWAVE Health, Inc.SNWV
$0-100%
NewAmsterdam Pharma Company logo
NewAmsterdam Pharma CompanyNAMS
-$5.94M+56.8%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$39K-32.8%
American Battery Technology Company logo
American Battery Technology CompanyABAT
$705.18K
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$480K+26.3%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
-$1.65M0.0%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept klrs:ChangeInFairValueOfDerivativeLiability.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's change in fair value of derivative liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's change in fair value of derivative liability?
KLRS (KLRS) reported change in fair value of derivative liability of $0 in Q1 2026.
How has KLRS's change in fair value of derivative liability changed year-over-year?
KLRS's change in fair value of derivative liability decreased by 100.0% year-over-year, from $1.23M to $0.
What does change in fair value of derivative liability mean?
Reflects the non-cash gain or loss resulting from the revaluation of derivative financial instruments held by the company. This metric captures volatility in the fair value of warrants, options, or embedded derivatives that must be marked-to-market each reporting period. It is a key indicator of how market-driven valuation changes affect the company's bottom line independent of core operations.